Locally Advanced Head and Neck Squamous Cell Carcinoma Clinical Trials

13 recruiting

Locally Advanced Head and Neck Squamous Cell Carcinoma Trials at a Glance

12 actively recruiting trials for locally advanced head and neck squamous cell carcinoma are listed on ClinicalTrialsFinder across 6 cities in 23 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Toronto, New Brunswick, and Baltimore. Lead sponsors running locally advanced head and neck squamous cell carcinoma studies include Groupe Oncologie Radiotherapie Tete et Cou, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, and AstraZeneca.

Browse locally advanced head and neck squamous cell carcinoma trials by phase

Treatments under study

About Locally Advanced Head and Neck Squamous Cell Carcinoma Clinical Trials

Looking for clinical trials for Locally Advanced Head and Neck Squamous Cell Carcinoma? There are currently 13 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Locally Advanced Head and Neck Squamous Cell Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Locally Advanced Head and Neck Squamous Cell Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 1

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

Locally Advanced Head and Neck Squamous Cell CarcinomaClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Stage III Hypopharyngeal Carcinoma AJCC v8+23 more
National Cancer Institute (NCI)46 enrolled18 locationsNCT05172245
Recruiting
Phase 3

Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Locally Advanced Head and Neck Squamous Cell Carcinoma
Ming-Yuan Chen430 enrolled1 locationNCT07524452
Recruiting
Phase 2

Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck

Locally Advanced Head and Neck Squamous Cell Carcinoma
Groupe Oncologie Radiotherapie Tete et Cou106 enrolled1 locationNCT06959108
Recruiting
Phase 3

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

Locally Advanced Head and Neck Squamous Cell Carcinoma
AstraZeneca1,145 enrolled305 locationsNCT06129864
Recruiting
Phase 1Phase 2

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+97 more
Mayo Clinic132 enrolled1 locationNCT05269381
Recruiting
Phase 2

Low-Dose Radiotherapy and Anti-PD-1 Immunotherapy as Neoadjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Locally Advanced Head and Neck Squamous Cell Carcinoma
Xiwei XU22 enrolled1 locationNCT07371234
Recruiting
Not Applicable

Comparison of Efficacy Between De-escalated Surgery and Standard Surgery After Neoadjuvant Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

Locally Advanced Head and Neck Squamous Cell Carcinoma
Qunxing Li,MD60 enrolled1 locationNCT07369882
Recruiting
Not Applicable

Low-Dose Weekly vs High-Dose Cisplatin

Locally Advanced Head and Neck Squamous Cell Carcinoma
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's100 enrolled3 locationsNCT03649048
Recruiting
Phase 2

Tirilizumab with Albumin-bound Paclitaxel and Cisplatin for Locally Advanced Resectable Oral Squamous Cell Carcinoma

Locally Advanced Head and Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University116 enrolled1 locationNCT06470217
Recruiting
Phase 1Phase 2

De-escalation Radiation Strategy After NAC in Combination With ICI in LAHNSCC

Locally Advanced Head and Neck Squamous Cell Carcinoma
Ruijin Hospital20 enrolled1 locationNCT06572514
Recruiting
Phase 2

A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood

Locally Advanced Head and Neck Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University104 enrolled1 locationNCT06240689
Recruiting

TPExtreme Induced Chemotherapy Followed by Surgery and Radiotherapy in the Oral Carcinoma.

Locally Advanced Head and Neck Squamous Cell CarcinomaOral Squamous Cell Carcinoma
Xiangya Hospital of Central South University124 enrolled1 locationNCT05872880